Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Annals of Oncology

Volumn 10, Issue 6, 1999, Pages 655-661

  Piro, L D ^a   White, C A ^c   Grillo Lopez A J ^c   Janakiraman, N ^d   Saven, A ^b   Beck, T M ^e   Varns, C ^c   Shuey, S ^c   Czuczman, M ^f   Lynch, J W ^g   Kolitz, J E ^h   Jain, V ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS CLINIC   (United States)

^c BIOGEN   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e St Luke's Mountain States Tumor Institute   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h NORTH SHORE UNIVERSITY HOSPITAL   (United States)

ⁱ TEXAS ONCOLOGY   (United States)

Author keywords

Bcl 2; CD20 antigen; Follicular NHL; Rituximab

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN BCL 2; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CHILL; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0032791210     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008389119525     Document Type: Article

References (19)

1. Miller R, Maloney D, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517-22.
2. Maloney D. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
3. Tedder T, Boyd A, Freedman A et al. The B-cell surface molecule B1 is functionally linked with B-cell activation and differentiation. J Immunol 1985; 135: 973 9.
4. Tedder T, Forsgren A, Boyd A et al. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 1986; 16: 881 7.
5. Golay J, Clark E, PCL B. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985; 135: 3795 801.
6. Clark E, Shu G, Ledbetter J. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci USA 1985; 82: 1766-70.
7. Tedder T, Zhou L, Bell P et al. The CD20 surface molecule of B lymphocytes functions as a calcium channel. J Cell Biochem 1990; 140: 195.
8. Einfeld D, Brown J, Valentine M et al. Molecular cloning of the human B-cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7: 711-7.
9. Press O, Appelbaum F, Ledbetter J et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 1987; 69: 584-91.
10. Maloney D, Smith B, Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88: 637a.
11. Stashenko P, Nadler L, Hardy R, Schlossman S. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-85.
12. Maloney D, Grillo-López A, Bodkin D et al. IDEC-C 2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-74.
13. Reff M, Carner K, Chambers K et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
14. Gribben J, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800 7.
15. FDA: Coding Symbols for Thesaurus of Adverse Reaction Terms, Fifth Edition. Rockville, MD: U.S. Food and Drug Administration 1995.
16. Ngan B-Y, Zehava C-L, Weiss L et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14:18) chromosomal translocation. N Engl J Med 1988; 318: 1638-44.
17. Aisenberg A, Wilkes B, Jacobson J. The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 1988; 71: 969-72.
18. Lee M-S, Blick M, Pathak S et al. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood 1987; 70: 90 5.
19. Yunis J, Oken M, Kaplan M et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982; 307: 1231-6.